Royalty Pharma Plc (NASDAQ:RPRX) is considered one of the best affordable biotech stocks to invest in now. TD Cowen analyst Michael Nedelcovych maintained a Buy rating with a price target of $42.00 on September 12. The company aims to meet or exceed its revenue target of $4.7 billion by 2030.

Nedelcovych highlighted Royalty Pharma Plc’s promising outlook and strong performance, noting its strategic position in the thriving biopharma ecosystem. The company collaborates with a range of innovators in the biopharmaceutical industry, from research hospitals and non-profits to global pharma companies.

Royalty Pharma Plc is a key player in funding innovation in the biopharmaceutical industry, both through direct partnerships for late-stage clinical trials and new product launches and by acquiring existing royalties from original innovators. Its portfolio includes royalties from over 35 commercial products, such as Tremfya and Imbruvica.

While Royalty Pharma Plc presents investment potential, some believe that certain AI stocks offer greater upside and less downside risk. For those seeking an undervalued AI stock that could benefit from current economic trends, exploring other options may be worthwhile.

Read more at Yahoo Finance: TD Cowen Maintains a Buy on Royalty Pharma (RPRX)